Discussion about this post

User's avatar
Neural Foundry's avatar

Solid analysis of how India's charting a middle path between rigid enforcement and innovation. The Schott Glass effects test mandate is huge, basically forces CCI to stop relying on formalistic approaches and actually prove harm. I've been following similar dynamics in EU where DMA implementation is turning into a compliance nightmare, so India's pause on ex-ante rules looks smart in hindsight. The patent vs competition law jurisdictional tangle is probaly the most interesting thread tho, creates massive uncertianty for pharma and tech companies operating there.

No posts

Ready for more?